Thalassemia and malignancy: An emerging concern?

Simple item page
dc.contributor.authorHodroj, Mohammad Hassan
dc.contributor.authorBou-Fakhredin, Rayan
dc.contributor.authorNour-Eldine, Wared
dc.contributor.authorNoureldine, Hussein A.
dc.contributor.authorNoureldine, Mohammad Hassan A.
dc.contributor.authorTaher, Ali T.
dc.contributor.departmentInternal Medicine
dc.contributor.departmentBiochemistry and Molecular Genetics
dc.contributor.departmentDivision of Hematology Oncology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:55:04Z
dc.date.available2025-01-24T11:55:04Z
dc.date.issued2019
dc.description.abstractThe thalassemias constitute a variable group of anemias that result from autosomal recessive inherited defects in the production of hemoglobin. The life expectancy of thalassemia patients has been extended over the last decades as a result of key milestones being achieved in optimizing management with transfusion and iron chelation therapy. Such advances have prolonged the survival of thalassemia patients and improved their overall quality of life. However, this increase in life expectancy has led to the manifestation of several morbidities, including multiple types of solid and hematologic malignancies. In this review we report the different types of solid and hematological malignancies that can develop in thalassemia patients, in addition to the possible predisposing factors and mechanisms behind their development. © 2019 Elsevier Ltd
dc.identifier.doihttps://doi.org/10.1016/j.blre.2019.06.002
dc.identifier.eid2-s2.0-85067667396
dc.identifier.pmid31253373
dc.identifier.urihttp://hdl.handle.net/10938/31188
dc.language.isoen
dc.publisherChurchill Livingstone
dc.relation.ispartofBlood Reviews
dc.sourceScopus
dc.subjectCancer
dc.subjectIron overload
dc.subjectMalignancies
dc.subjectThalassemia
dc.subjectTransfusion
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectDeferiprone
dc.subjectDeferoxamine
dc.subjectHydroxyurea
dc.subjectRuxolitinib
dc.subjectSorafenib
dc.subjectAcute lymphoblastic leukemia
dc.subjectBeta thalassemia
dc.subjectBlood transfusion
dc.subjectBone marrow
dc.subjectBreast cancer
dc.subjectChemoembolization
dc.subjectDisease predisposition
dc.subjectHepatitis c
dc.subjectHormone substitution
dc.subjectHuman
dc.subjectHuman t cell leukemia virus infection
dc.subjectLife expectancy
dc.subjectLiver cell carcinoma
dc.subjectLiver resection
dc.subjectLiver transplantation
dc.subjectLymphoma
dc.subjectMorbidity
dc.subjectMyeloproliferative neoplasm
dc.subjectNephrectomy
dc.subjectOverall survival
dc.subjectPercutaneous radiofrequency thermoablation
dc.subjectPopulation research
dc.subjectPriority journal
dc.subjectQuality of life
dc.subjectRadiofrequency ablation
dc.subjectRenal cell carcinoma
dc.subjectReview
dc.subjectThyroid papillary carcinoma
dc.subjectComplication
dc.subjectNeoplasm
dc.titleThalassemia and malignancy: An emerging concern?
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2019-7371.pdf
Size:
646.81 KB
Format:
Adobe Portable Document Format
Download

Collections

Internal Medicine
Biochemistry and Molecular Genetics